

## Shasun Pharma to sell 12% stake to PE firm

Our Bureau

Chennai, Feb. 27

Mauritius-based private equity investor Caduceus Asia Mauritius is to pick up 11.93 per cent stake in Shasun Pharmaceuticals for Rs 50 crore.

Promoter holding in Shasun will come to 41.15 per cent from 46.73 per cent.

Shasun at its board meeting decided to allot up to 65 lakh equity shares of face value Rs 2 for cash at a price of Rs 76 a share (including a premium of Rs 74 a share) aggregating to about Rs 50 crore to M/s Caduceus Asia Mauritius Ltd.

Caduceus is the investment arm of OrbiMed, a US-based private equity fund focused on the healthcare sector. OrbiMed's earlier investments are in Bharat Serums and Vaccines and Ecron Acunova, a Manipal group-owned clinical research organisation.

Through the issue, Shasun

plans to raise long-term funds to partially finance its capital expenditure for financial year 2012-13, including a manufacturing plant in Vizag, and long-term working capital requirements, said the company in a statement.

The holding of financial institutions, banks and mutual funds will come down to 14.57 per cent from 16.54 per cent. Public shareholding will come down to 27.69 per cent from 31.44 per cent.

Malabar Capital Advisors is the financial advisor to Shasun on this transaction.

The issue is subject to approval of shareholders. An extraordinary general meeting is being convened on March 22 to obtain the approval. The allotment of shares will be completed within 15 days of passing the special resolution by shareholders.

swethak@thehindu.co.in